Ventricular Fibrillation and Atrial Fibrillation

Ventricular Fibrillation and Atrial Fibrillation
Emerging Antiarrhythmics in the Context of Current Devices, Interventions and Pharmacological Agents

Although ventricular and atrial fibrillation represent the most common cardiac arrhymias and are associated with amongst the highest rates of cardiovascular morbidity and mortality, treatment options are suboptimal.  New opportunities are however approaching the market, notably Cardiome’s RSD1235, paving the way for development by others.

LeadDiscovery's most recent report discusses current pharmacological and interventional treatments of ventricular and atrial fibrillation paying especial attention to unmet needs and drivers of future development.  The report then provides a detailed proof of concept of emerging molecular targets for next generation therapeutics and critical profiles of pipeline candidates.  The report is of equal use to companies with developmental and marketed devices and those involved in drug development.  For the former the report sets out the competitive landscape while on the other hand it identifies areas where pharmacological and interventional approaches can meet; on the other hand the report represents an invaluable intelligence tool to those companies looking to develop novel and more effective antiarrhythmics.  The report was produced with both research and business development personnel in mind. [more on this report]